New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2012
06:10 EDTAKRXAkorn announces approval and launch of generic Prometrium
Akorn announced that its manufacturing and development partner, Sofgen Pharmaceuticals has received approval of its abbreviated new drug application, or ANDA, for Progesterone capsules, 100mg and 200mg. The approved ANDA is for the generic of Abbott Laboratories' Prometrium capsules indicated for the treatment of endometrial hyperplasia and secondary amenorrhea. Akorn has exclusive marketing rights to Sofgen's product in the U.S. and the Company has begun distribution. According to IMS Health, Progesterone capsules, 100mg and 200mg, had combined sales of approximately $170M in the U.S. based on annualizing the three months ended August 31. IMS Health sales figures exclude certain customary discounts and incentives.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:24 EDTAKRXJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
06:45 EDTAKRXAkorn risk/reward compelling into restatements, says JPMorgan
Subscribe for More Information
May 18, 2015
07:21 EDTAKRXAkorn receives NASDAQ delinquency notice
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use